Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Abraham Nissani"'
Autor:
Ronnie Shapira-Frommer, Elad Jacoby, Orit Itzhaki, Abraham Nissani, Gal Markel, Jacob Schachter, Shaked Lev-Ari, Tomer Meirson, Nethanel Asher, Guy Ben-Betzalel, Michal J. Besser
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Background Adoptive cell therapy with T cells genetically engineered to express a chimeric antigen receptor (CAR-T) or tumor-infiltrating T lymphocytes (TIL) demonstrates impressive clinical results in patients with cancer. Lymphodepleting preconditi
Externí odkaz:
https://doaj.org/article/b123a9cc796845809ac8adf818ec97d0
Autor:
Liat Ninio, Abraham Nissani, Tomer Meirson, Tom Domovitz, Alessandro Genna, Shams Twafra, Kolluru D. Srikanth, Roba Dabour, Erez Avraham, Ateret Davidovich, Hava Gil-Henn, Meital Gal-Tanamy
Publikováno v:
Cells, Vol 8, Iss 11, p 1395 (2019)
Hepatocellular carcinoma (HCC) represents the fifth most common cancer worldwide and the third cause of cancer-related mortality. Hepatitis C virus (HCV) is the leading cause of chronic hepatitis, which often results in liver fibrosis, cirrhosis, and
Externí odkaz:
https://doaj.org/article/2116a9b99f8f4498835802f3524446f8
Autor:
Michal J. Besser, Elad Jacoby, Orit Itzhaki, Guy Ben-Betzalel, Shaked Lev-Ari, Nethanel Asher, Gal Markel, Jacob Schachter, Ronnie Shapira-Frommer, Tomer Meirson, Abraham Nissani
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
BackgroundAdoptive cell therapy with T cells genetically engineered to express a chimeric antigen receptor (CAR-T) or tumor-infiltrating T lymphocytes (TIL) demonstrates impressive clinical results in patients with cancer. Lymphodepleting preconditio
Autor:
Helly Vernitsky, Abraham Nissani, Adva Kubi, Gal Markel, Jacob Schachter, Karin Brezinger, Michal Levi, Michal J. Besser, Meir Rozenbaum, Hadar Brayer, Elad Jacoby, Orit Itzhaki, Amos Toren, Li at Zeltzer, Abraham Avigdor, Arnon Nagler
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundCD19 chimeric antigen receptor T (CAR-T) cells demonstrate remarkable remission rates in pediatric and adult patients with refractory or relapsed (r/r) acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL). In 2016, we initiat
Autor:
Douglas Zippel, Avichai Shimoni, Karin Brezinger, Ronnie Shapira-Frommer, Dragoslav Zikich, Alon Ben-Nun, Arnon Nagler, Jacob Schachter, Li‐at Zeltzer, Michal J. Besser, Orit Itzhaki, Gal Markel, Michal Levi, Nethanel Asher, Abraham Nissani, Adva Kubi, Guy Ben-Betzalel
Publikováno v:
Molecular carcinogenesisREFERENCES. 59(7)
Adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TIL) mediates objective responses in 30% to 50% of patients with metastatic melanoma according to multiple, small phase 2 trials. Here we report the long-term clinical results, intent-to
Autor:
Alessandro Genna, Liat Ninio, Kolluru D. Srikanth, Meital Gal-Tanamy, Roba Dabour, Tom Domovitz, Abraham Nissani, Shams Twafra, Hava Gil-Henn, Ateret Davidovich, Erez Avraham, Tomer Meirson
Publikováno v:
Cells
Volume 8
Issue 11
Cells, Vol 8, Iss 11, p 1395 (2019)
Volume 8
Issue 11
Cells, Vol 8, Iss 11, p 1395 (2019)
Hepatocellular carcinoma (HCC) represents the fifth most common cancer worldwide and the third cause of cancer-related mortality. Hepatitis C virus (HCV) is the leading cause of chronic hepatitis, which often results in liver fibrosis, cirrhosis, and